217 related articles for article (PubMed ID: 30952644)
1. Clinical and Genome-wide Analysis of Cisplatin-induced Tinnitus Implicates Novel Ototoxic Mechanisms.
El Charif O; Mapes B; Trendowski MR; Wheeler HE; Wing C; Dinh PC; Frisina RD; Feldman DR; Hamilton RJ; Vaughn DJ; Fung C; Kollmannsberger C; Mushiroda T; Kubo M; Gamazon ER; Cox NJ; Huddart R; Ardeshir-Rouhani-Fard S; Monahan P; Fossa SD; Einhorn LH; Travis LB; Dolan ME
Clin Cancer Res; 2019 Jul; 25(13):4104-4116. PubMed ID: 30952644
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive Audiometric Analysis of Hearing Impairment and Tinnitus After Cisplatin-Based Chemotherapy in Survivors of Adult-Onset Cancer.
Frisina RD; Wheeler HE; Fossa SD; Kerns SL; Fung C; Sesso HD; Monahan PO; Feldman DR; Hamilton R; Vaughn DJ; Beard CJ; Budnick A; Johnson EM; Ardeshir-Rouhani-Fard S; Einhorn LH; Lipshultz SE; Dolan ME; Travis LB
J Clin Oncol; 2016 Aug; 34(23):2712-20. PubMed ID: 27354478
[TBL] [Abstract][Full Text] [Related]
3. Clinical and Genome-Wide Analysis of Multiple Severe Cisplatin-Induced Neurotoxicities in Adult-Onset Cancer Survivors.
Trendowski MR; Wheeler HE; El-Charif O; Feldman DR; Hamilton RJ; Vaughn DJ; Fung C; Kollmannsberger C; Einhorn LH; Travis LB; Dolan ME
Clin Cancer Res; 2020 Dec; 26(24):6550-6558. PubMed ID: 32998964
[TBL] [Abstract][Full Text] [Related]
4. Prevalence and risk factors for ototoxicity after cisplatin-based chemotherapy.
Sanchez VA; Dinh PC; Rooker J; Monahan PO; Althouse SK; Fung C; Sesso HD; Einhorn LH; Dolan ME; Frisina RD; Travis LB
J Cancer Surviv; 2023 Feb; 17(1):27-39. PubMed ID: 36637632
[TBL] [Abstract][Full Text] [Related]
5. Pharmacogenomics of cisplatin-induced neurotoxicities: Hearing loss, tinnitus, and peripheral sensory neuropathy.
Zhang X; Trendowski MR; Wilkinson E; Shahbazi M; Dinh PC; Shuey MM; ; Feldman DR; Hamilton RJ; Vaughn DJ; Fung C; Kollmannsberger C; Huddart R; Martin NE; Sanchez VA; Frisina RD; Einhorn LH; Cox NJ; Travis LB; Dolan ME
Cancer Med; 2022 Jul; 11(14):2801-2816. PubMed ID: 35322580
[TBL] [Abstract][Full Text] [Related]
6. Hearing loss before and after cisplatin-based chemotherapy in testicular cancer survivors: a longitudinal study.
Haugnes HS; Stenklev NC; Brydøy M; Dahl O; Wilsgaard T; Laukli E; Fosså SD
Acta Oncol; 2018 Aug; 57(8):1075-1083. PubMed ID: 29384420
[TBL] [Abstract][Full Text] [Related]
7. Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer.
Bokemeyer C; Berger CC; Hartmann JT; Kollmannsberger C; Schmoll HJ; Kuczyk MA; Kanz L
Br J Cancer; 1998 Apr; 77(8):1355-62. PubMed ID: 9579846
[TBL] [Abstract][Full Text] [Related]
8. Genetic risk factors of cisplatin induced ototoxicity in adult patients.
Talach T; Rottenberg J; Gal B; Kostrica R; Jurajda M; Kocak I; Lakomy R; Vogazianos E
Neoplasma; 2016; 63(2):263-8. PubMed ID: 26774148
[TBL] [Abstract][Full Text] [Related]
9. Clinical and genetic risk factors for radiation-associated ototoxicity: A report from the Childhood Cancer Survivor Study and the St. Jude Lifetime Cohort.
Trendowski MR; Baedke JL; Sapkota Y; Travis LB; Zhang X; El Charif O; Wheeler HE; Leisenring WM; Robison LL; Hudson MM; Morton LM; Oeffinger KC; Howell RM; Armstrong GT; Bhatia S; Dolan ME
Cancer; 2021 Nov; 127(21):4091-4102. PubMed ID: 34286861
[TBL] [Abstract][Full Text] [Related]
10. The genetic vulnerability to cisplatin ototoxicity: a systematic review.
Tserga E; Nandwani T; Edvall NK; Bulla J; Patel P; Canlon B; Cederroth CR; Baguley DM
Sci Rep; 2019 Mar; 9(1):3455. PubMed ID: 30837596
[TBL] [Abstract][Full Text] [Related]
11. Genetic variation in Otos is associated with cisplatin-induced ototoxicity.
Spracklen TF; Whitehorn H; Vorster AA; Ramma L; Dalvie S; Ramesar RS
Pharmacogenomics; 2014 Sep; 15(13):1667-76. PubMed ID: 25410892
[TBL] [Abstract][Full Text] [Related]
12. [Detection of ototoxic effect of cisplatin with otoacoustic emission in testicular cancer patients].
Biró K
Magy Onkol; 2009 Sep; 53(3):279-83. PubMed ID: 19793694
[TBL] [Abstract][Full Text] [Related]
13. Usefulness of current candidate genetic markers to identify childhood cancer patients at risk for platinum-induced ototoxicity: Results of the European PanCareLIFE cohort study.
Langer T; Clemens E; Broer L; Maier L; Uitterlinden AG; de Vries ACH; van Grotel M; Pluijm SFM; Binder H; Mayer B; von dem Knesebeck A; Byrne J; van Dulmen-den Broeder E; Crocco M; Grabow D; Kaatsch P; Kaiser M; Spix C; Kenborg L; Winther JF; Rechnitzer C; Hasle H; Kepak T; van der Kooi AF; Kremer LC; Kruseova J; Bielack S; Sorg B; Hecker-Nolting S; Kuehni CE; Ansari M; Kompis M; van der Pal H; Parfitt R; Deuster D; Matulat P; Tillmanns A; Tissing WJE; Beck JD; Elsner S; Am Zehnhoff-Dinnesen A; van den Heuvel-Eibrink MM; Zolk O;
Eur J Cancer; 2020 Oct; 138():212-224. PubMed ID: 32905960
[TBL] [Abstract][Full Text] [Related]
14. Ototoxicity After Cisplatin-Based Chemotherapy: Factors Associated With Discrepancies Between Patient-Reported Outcomes and Audiometric Assessments.
Ardeshirrouhanifard S; Fossa SD; Huddart R; Monahan PO; Fung C; Song Y; Dolan ME; Feldman DR; Hamilton RJ; Vaughn D; Martin NE; Kollmannsberger C; Dinh P; Einhorn L; Frisina RD; Travis LB
Ear Hear; 2022; 43(3):794-807. PubMed ID: 35067571
[TBL] [Abstract][Full Text] [Related]
15. Variants in
Wheeler HE; Gamazon ER; Frisina RD; Perez-Cervantes C; El Charif O; Mapes B; Fossa SD; Feldman DR; Hamilton RJ; Vaughn DJ; Beard CJ; Fung C; Kollmannsberger C; Kim J; Mushiroda T; Kubo M; Ardeshir-Rouhani-Fard S; Einhorn LH; Cox NJ; Dolan ME; Travis LB
Clin Cancer Res; 2017 Jul; 23(13):3325-3333. PubMed ID: 28039263
[No Abstract] [Full Text] [Related]
16. Clinical and Genome-Wide Analysis of Serum Platinum Levels after Cisplatin-Based Chemotherapy.
Trendowski MR; El-Charif O; Ratain MJ; Monahan P; Mu Z; Wheeler HE; Dinh PC; Feldman DR; Ardeshir-Rouhani-Fard S; Hamilton RJ; Vaughn DJ; Fung C; Kollmannsberger C; Mushiroda T; Kubo M; Hannigan R; Strathmann F; Einhorn LH; Fossa SD; Travis LB; Dolan ME
Clin Cancer Res; 2019 Oct; 25(19):5913-5924. PubMed ID: 31296530
[TBL] [Abstract][Full Text] [Related]
17. Risk factors associated with cisplatin-induced ototoxicity in Japanese patients with solid tumors.
Okada H; Kitagawa K
Cancer Med; 2023 Apr; 12(7):7904-7910. PubMed ID: 36567514
[TBL] [Abstract][Full Text] [Related]
18. Speech perception 30 years after cisplatin-based chemotherapy in adults: limited clinical relevance of long-term ototoxicity?
Skalleberg J; Myhrum M; Småstuen MC; Osnes TA; Fosså SD; Bunne M
Acta Oncol; 2021 Apr; 60(4):426-433. PubMed ID: 33617403
[TBL] [Abstract][Full Text] [Related]
19. Tinnitus onset rates from chemotherapeutic agents and ototoxic antibiotics: results of a large prospective study.
Dille MF; Konrad-Martin D; Gallun F; Helt WJ; Gordon JS; Reavis KM; Bratt GW; Fausti SA
J Am Acad Audiol; 2010 Jun; 21(6):409-17. PubMed ID: 20701838
[TBL] [Abstract][Full Text] [Related]
20. Characteristics and risk factors of cisplatin-induced ototoxicity in testicular cancer patients detected by distortion product otoacoustic emission.
Biro K; Noszek L; Prekopp P; Nagyiványi K; Géczi L; Gaudi I; Bodrogi I
Oncology; 2006; 70(3):177-84. PubMed ID: 16757924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]